Scholars Central

Conference abstractPublished 17 Oct 2016

Fusion molecules as a new concept to take chemotherapy to the next level

Authors: Thomas Mehrling

Mundipharma EDO GmbH, Switzerland

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Past attempts to improve treatment efficacy, by inventing various combinations of cytotoxic agents, have provided disappointing results. Patients, mostly treated in large cooperative trials, experienced little benefit from intensification of dose and schedule but instead suffered from frequent and severe adverse reactions. Classical chemotherapy now finds itself at a crossroad. In some cancers, treatment is increasingly reliant on just targeted therapies; whereas in others the demand for a less toxic combination of chemotherapy and targeted therapies creates the need for different drugs or âÂ?Â?smarterâÂ?Â? ways to deliver chemotherapy to the tumor. As demand drives innovation chemotherapy is about to evolve, more effectively targeting tumor cells while reducing damage to healthy tissues. Two important trends are emerging: The development of antibodydrug conjugates (ADCs) and the exploitation of synergies of targeted and cytotoxic therapy through fusion molecules. Fusion molecules combine an established chemotherapy principle with a synergistic targeted mode of action in one molecule. By exerting their dual action simultaneously, fusion molecules may overcome the difficulties of combining single agents with different pharmacokinetics and other pharmacological factors. One fusion molecule, currently in development, combines the strong alkylating activity of bendamustine with the histone-deacetylase (HDAC) inhibitor vorinostat. The synergies of HDACinhibition and DNA-damaging agents, such as alkylators, provided the rationale for the synthesis of the first-in-class fusion molecule bendamustine-vorinostat. It is anticipated that this fusion molecule may have strong activity in various hematological malignancies and solid tumors.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Hematology & Thromboembolic Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Hematology & Thromboembolic Diseases
  • SubjectHaematology
  • BylineArticles whose byline prints “Thomas Mehrling”